Form 8-K
8-K — CODEXIS, INC.
Accession: 0001193125-26-458492
Filed: 2026-11-12
Period: 2026-11-12
CIK: 0001200375
SIC: 2860 (INDUSTRIAL ORGANIC CHEMICALS)
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — d189706d8k.htm (Primary)
EX-99.1 (d189706dex991.htm)
GRAPHIC (g189706g1113012950841.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: d189706d8k.htm · Sequence: 1
8-K
false 0001200375 0001200375 2026-11-12 2026-11-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2026
Codexis, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-34705
71-0872999
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
200 Penobscot Drive
Redwood City, CA 94063
(Address of Principal Executive Offices) (Zip Code)
(650) 421-8100
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading
Symbol(s)
Name of Each Exchange
on Which Registered
Common Stock, par value $0.0001 per share
CDXS
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On November 12, 2026, Codexis, Inc. announced its financial results for the quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01
Financial Statements and Exhibits.
Exhibit
No.
Description
99.1
Press release dated November 12, 2026 relating to the financial results for the quarter ended September 30, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CODEXIS, INC.
Date: November 12, 2026
By:
/s/ Georgia Erbez
Georgia Erbez
Chief Financial Officer and Chief Business Officer
EX-99.1
EX-99.1
Filename: d189706dex991.htm · Sequence: 2
EX-99.1
Exhibit 99.1
Codexis, Inc.
200 Penobscot Drive
Redwood City, CA 94063
+1 (650)
421-8100
codexis.com
Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update
Reports revenue of $19.3 million for the third quarter of 2026, company reiterates full-year revenue guidance
Shared new advances in RNA therapeutic manufacturing at TIDES Europe
Entered into a $60 million term loan facility with Trinity Capital; initial tranche used to refinance current debt
REDWOOD CITY, Calif., November 12, 2026 — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for
efficient and scalable manufacturing of complex therapeutics, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.
“I am pleased with our outstanding progress in 2026, through both innovation and technical achievements, that has garnered attention from leading
innovators in the siRNA field,” stated Alison Moore, PhD, President and Chief Executive Officer of Codexis. “Last week we presented new data at the TIDES Europe annual meeting showing successful
scale-up of the ECO Synthesis® Manufacturing Platform at 100-gram scale with high product quality, and including
improved process performance with reduced cycle time. In addition, we significantly strengthened our balance sheet with an equity raise of approximately $25 million in net proceeds, completed in July. This was followed by a $60 million
term loan agreement which we closed earlier this month, of which $42.5 million was used to refinance our existing debt. We have made significant progress in industrializing our technology while simultaneously increasing our revenue base,
managing expenses, and improving the financial stability of our company.”
Third Quarter and Recent Business Highlights
•
In November, the company completed a $60 million senior secured loan agreement with Trinity Capital. The
first tranche of $42.5 million was used to replace the existing agreement the company had with Innovatus Life Sciences Lending Fund I, LP. The remainder of the facility is available for future drawdown, subject to certain conditions.
•
In November, Codexis hosted key presentations at the 2026 TIDES Europe annual meeting. These presentations
demonstrated successful production of 100 grams of high-quality oligonucleotide. The company also showed greater potency of stereo-defined siRNA as compared to chemically synthesized material. These presentations have continued to expand
industry-wide interest in the ECO Synthesis Manufacturing Platform.
•
In October, Codexis announced a feasibility study with a pioneer company in the siRNA field, where Codexis will
use its ECO Synthesis technology to synthesize stereo-defined fragments. This innovator uses a fragment synthesis and ligation strategy and is seeking a method to increase the purity of fragments above what can be attained using standard solid phase
chemistry techniques.
•
The company successfully completed an equity financing in July that raised a total of approximately
$25 million in net proceeds.
Upcoming Milestones
•
Advance its partnerships with drug innovators toward clinical stage manufacturing agreements.
•
Codexis expects to begin retrofit construction for its ECO GMP Manufacturing Center in the new year, with the
facility being operational by the end of 2027. The purpose of this facility is to provide siRNA material for preclinical investigations and Phase 1 and 2 clinical trials.
•
Expand relationships with existing and future CDMO partners with a goal of commencing a strategic partner
agreement.
Third Quarter 2026 Financial Highlights
•
Total revenues were $19.3 million for the third quarter of 2026 compared to $8.6 million in the third
quarter of 2025. The increase was primarily due to higher product revenue, driven by the approval and launch of new products by our customers with higher margins compared to more established products.
•
Product gross margin was 74.5% for the third quarter of 2026, compared to 64% in the third quarter of 2025. The
increase in gross margin was largely due to a shift in sales toward more profitable products, and declines in less profitable, established products.
•
Research and Development expenses for the third quarter of 2026 were $12.6 million compared to
$13.9 million in the third quarter of 2025. The decrease was primarily due to lower employee-related costs, reduced spending on outside services and lower lab supplies, partially offset by higher allocable costs.
•
Selling, General & Administrative expenses for the third quarter of 2026 were $10.1 million
compared to $11.2 million in the third quarter of 2025. The decrease was primarily due to lower employee-related costs associated with reduced headcount, lower stock-based compensation expenses, and lower allocable costs, partially offset by
higher facility-related expenses.
•
The net loss for the third quarter of 2026 was $8.1 million, or $0.08 per share, compared to a net loss of
$19.6 million, or $0.22 per share, for the third quarter of 2025.
•
As of September 30, 2026, Codexis had $72.7 million in cash, cash equivalents, and short-term
investments. During the third quarter, Codexis successfully completed an equity financing that raised a total of approximately $25 million in net proceeds. In addition, after the close of the third quarter Codexis entered into a
$60 million term loan facility with a $42.5 million drawdown at closing, which was used to retire existing debt.
2026
Financial Revenue Guidance Reiterated, Gross Margin Estimate Increased
Codexis reiterated and updated its full-year 2026 financial guidance as
follows:
•
Total revenues are expected to be in the range of $72 million to $76 million. Gross margin for the year
2026 is expected to be in the low 70% range.
•
Codexis expects that its existing cash, cash equivalents, and short-term investments will be sufficient to fund
its planned operations through the end of 2028. The financial guidance and cash runway projections include the expenses associated with the build out of the GMP production facility.
Page | 2
Conference Call and Webcast
Codexis will hold a conference call and webcast today beginning at 4:30 pm ET. A live webcast will be available on the Investors section of the Company website
at ir.codexis.com. The conference call dial-in numbers are 877-705-2976 for domestic callers and 201-689-8798 for international callers.
A webcast replay will be available on
the Investors section of the Company website, beginning approximately two hours after the completion of the call.
About Codexis
Codexis® is a leading provider of high-performance enzymatic solutions for efficient and scalable
therapeutics manufacturing. The company is currently developing its proprietary ECO Synthesis® Manufacturing Platform, an aqueous enzymatic process that may offer a scalable alternative to
traditional solid phase organic synthesis of oligonucleotide manufacturing. Initially, Codexis is applying its technology to address the rapidly growing demand for RNAi therapeutics. Codexis’ unique enzymes can drive improvements such as
higher yields, increased purity, reduced energy usage and waste generation, stereoisomer control of siRNA, and improved overall capacity in manufacturing at substantially lower capital requirements, all of which may lead to greater efficiency and
reduced costs. In addition, the company supplies high-performance enzymes through its BioCatalysis business that are used in the manufacture of multiple commercially available small molecule therapeutics. For additional information, please visit
https://www.codexis.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,”
“contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,”
“plan,” “positioned,” “potential,” “predict,” “forecast,” “guidance,” “look forward to,” “milestone,” “on track,” “outlook,”
“project,” “runway,” “seek,” “should,” “suggest,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future
events and future trends, or the negative of these terms or other comparable terminology. To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the
current beliefs and expectations of management. These forward-looking statements include, but are not limited to, statements regarding anticipated milestones, including technical milestones, data releases and public announcements related thereto;
Codexis’ expectation that its existing cash, cash equivalents and short-term investments will be sufficient to fund its planned operations, including the expenses associated with the build out of its GMP production facility; Codexis’
financial guidance; the receipt of required permits and approvals for, and the timing, cost and completion of, the retrofit construction of Codexis’ ECO GMP Manufacturing Center, the anticipated timing of the commencement of retrofit
construction and the facility being operational, and the intended use of the facility to supply siRNA material for preclinical investigations and clinical trials; Codexis’ ability to advance partnerships with drug innovators toward clinical
stage manufacturing agreements; Codexis’ ability to expand relationships with CDMO partners and to commence a strategic partner agreement; the availability of the remainder of Codexis’ loan facility for future drawdown, subject to
certain conditions; Codexis’ feasibility study; and the anticipated benefits, performance, sustainability and commercial potential of Codexis’ ECO Synthesis® Manufacturing Platform
and the anticipated level of customer interest in and adoption of Codexis’ technology. The forward-looking statements in this press release are subject to the safe harbor created by these sections, speak only as of the date of this press
release, and are qualified by the cautionary statements set forth below. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases,
beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators and the risk that collaborators
may terminate their development programs under their respective license agreements with Codexis; Codexis’ dependence on a limited number of products and customers, and potential adverse effects to Codexis’ business if its
customers’ products are not received well in the markets; Codexis’ ability to successfully develop and commercialize new technology and
Page | 3
products for its target markets, including its ECO Synthesis® Manufacturing Platform; the risk that competitors and potential competitors
who have greater resources and experience than Codexis may develop products and technologies that make Codexis’ products and technologies obsolete; Codexis’ ability to advance partnerships with drug innovators toward clinical stage
manufacturing agreements and to establish strategic partnerships with CDMOs; the timing, cost and successful completion of the retrofit construction of Codexis’ GMP facility and the risk that the facility may not achieve operational readiness
on the anticipated timeline; the risk that the FDA or other regulatory authorities may not accept enzymatically synthesized oligonucleotides or that the regulatory pathway for ECO Synthesis-derived products may be longer or more uncertain than
anticipated; risks relating to Codexis’ dependence on its GMP facility, and the risk of delays or cost overruns; the concentration of Codexis’ revenue in a limited number of contracts and milestones; Codexis’ potential need for
additional capital in the future in order to expand its business and the risk that additional capital may not be available on acceptable terms or at all; Codexis’ ability to comply with debt covenants under its loan facility and to satisfy
scheduled principal and interest payment obligations, and the effect of the terms of that facility on Codexis’ liquidity and operating flexibility; risks relating to Codexis’ ability to obtain, maintain, defend and enforce patents, trade
secrets and other intellectual property rights covering its technologies, and the risk of intellectual property infringement claims by third parties; Codexis’ dependence on key personnel and its ability to attract and retain qualified
employees; Codexis’ reliance on third-party suppliers; risks relating to cybersecurity incidents and data integrity; volatility in the market price of Codexis’ common stock and its ability to maintain compliance with Nasdaq listing
requirements; Codexis’ ability to accurately forecast financial and operational performance; the impact of market, political and economic conditions on Codexis’ business, financial condition and share price; and the impact of
international trade policies, including tariffs, sanctions and trade barriers, on Codexis’ business. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 11, 2026, and in Codexis’ Quarterly Report on Form 10-Q for the quarterly period ended
September 30, 2026, to be filed with the SEC, in each case including under the caption “Risk Factors,” and in Codexis’ other filings with the SEC. Codexis expressly disclaims any intent or obligation to update these
forward-looking statements, except as required by law. Codexis’ results presented in this press release are not necessarily indicative of Codexis’ operating results for any future periods.
For More Information
Investor Contact
Georgia Erbez
(650)
421-8100
ir@codexis.com
Page | 4
Codexis, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In
Thousands, Except Per Share Amounts)
Three Months Ended September 30,
Nine Months Ended September 30,
2026
2025
2026
2025
Revenues:
Product revenue
$
15,740
$
6,807
$
36,149
$
20,246
Research and development revenue
3,522
1,794
13,277
11,226
Total revenues
19,262
8,601
49,426
31,472
Costs and operating expenses:
Cost of product revenue
4,014
2,465
9,590
7,295
Research and development
12,587
13,868
35,741
40,586
Selling, general and administrative
10,097
11,217
30,803
35,889
Total costs and operating expenses
26,698
27,550
76,134
83,770
Loss from operations
(7,436
)
(18,949
)
(26,708
)
(52,298
)
Interest income
658
634
1,859
1,969
Interest and other expense, net
(1,341
)
(1,292
)
(3,933
)
(3,217
)
Loss before income taxes
(8,119
)
(19,607
)
(28,782
)
(53,546
)
Provision for income taxes
9
8
55
29
Net loss
$
(8,128
)
$
(19,615
)
$
(28,837
)
$
(53,575
)
Net loss per share, basic and diluted
$
(0.08
)
$
(0.22
)
$
(0.30
)
$
(0.62
)
Weighted average common stock shares used in computing net loss per share, basic and
diluted
107,259
90,251
96,507
86,045
Codexis, Inc.
Condensed Consolidated Statements of Comprehensive Loss
(Unaudited)
(In
Thousands)
Three Months Ended September 30,
Nine Months Ended September 30,
2026
2025
2026
2025
Net loss
$
(8,128
)
$
(19,615
)
$
(28,837
)
$
(53,575
)
Other comprehensive income (loss):
Unrealized income (loss) on
available-for-sale short-term investments, net of tax
(42
)
15
(63
)
(40
)
Comprehensive loss
$
(8,170
)
$
(19,600
)
$
(28,900
)
$
(53,615
)
Page | 5
Codexis, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In
Thousands)
September 30, 2026
December 31, 2025
Assets
Current assets:
Cash and cash equivalents
$
29,213
$
50,793
Restricted cash, current
—
478
Short-term investments
43,446
27,416
Financial assets:
Accounts receivable
6,499
8,757
Contract assets
8,590
492
Unbilled receivables
604
1,480
Total financial assets
15,693
10,729
Less: allowances
(43
)
(43
)
Total financial assets, net
15,650
10,686
Inventories
2,096
1,817
Prepaid expenses and other current assets
5,360
5,626
Total current assets
95,765
96,816
Restricted cash
1,612
1,612
Investment in non-marketable equity securities
2,498
2,498
Right-of-use
assets - Operating leases, net
27,659
30,501
Property and equipment, net
13,329
13,024
Goodwill
2,463
2,463
Other non-current assets
895
883
Total assets
$
144,221
$
147,797
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
$
5,760
$
1,554
Accrued compensation
8,751
11,042
Other accrued liabilities
4,105
2,768
Current portion of lease obligations - Operating leases
2,946
2,944
Current portion of long-term debt
11,793
—
Deferred revenue
735
7,009
Total current liabilities
34,090
25,317
Deferred revenue, net of current portion
—
360
Long-term lease obligations - Operating leases
28,043
30,159
Long-term debt
29,485
40,105
Other long-term liabilities
1,365
1,327
Total liabilities
92,983
97,268
Stockholders’ equity:
Common stock
11
9
Additional paid-in capital
686,899
657,292
Accumulated other comprehensive income (loss)
(55
)
8
Accumulated deficit
(635,617
)
(606,780
)
Total stockholders’ equity
51,238
50,529
Total liabilities and stockholders’ equity
$
144,221
$
147,797
Page | 6
GRAPHIC
GRAPHIC
Filename: g189706g1113012950841.jpg · Sequence: 6
Binary file (5980 bytes)
Download g189706g1113012950841.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.3
Document and Entity Information
Nov. 12, 2026
Cover [Abstract]
Amendment Flag
false
Entity Central Index Key
0001200375
Document Type
8-K
Document Period End Date
Nov. 12, 2026
Entity Registrant Name
Codexis, Inc.
Entity Incorporation State Country Code
DE
Entity File Number
001-34705
Entity Tax Identification Number
71-0872999
Entity Address, Address Line One
200 Penobscot Drive
Entity Address, City or Town
Redwood City
Entity Address, State or Province
CA
Entity Address, Postal Zip Code
94063
City Area Code
(650)
Local Phone Number
421-8100
Written Communications
false
Soliciting Material
false
Pre Commencement Tender Offer
false
Pre Commencement Issuer Tender Offer
false
Security 12b Title
Common Stock, par value $0.0001 per share
Trading Symbol
CDXS
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration